Dabigatran in prevention of venous thromboembolism

Current anticoagulants have serious side effects, primarily hemorrhage, and the process of adjusting the dosage to make the therapy effective and safe is complicated. Dabigatran is a new anticoagulant, a non-peptide, highly specific thrombin inhibitor. The review presents results of clinical studies which have demonstrated that dabigatran is not inferior to warfarin in effective prevention of recurrent venous thromboembolism (VTE), safety, and convenience of use.